LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Published 2022 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume 33, Issue -, Pages S1386

Publisher

Elsevier BV

Online

2022-09-14

DOI

10.1016/j.annonc.2022.08.012

Ask authors/readers for more resources

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Add your recorded webinar

Ask a Question. Answer a Question.